From: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
Genotype
N
%
Median TTF
(months)
p value
Median OS
CYP2C19
EM
266
78
28.7
0.4
(0.4)
73.9
(0.5)
IM + PM
73
22
25.1
65.6
CYP2D6
UM + EM
127
56
30.7
0.9
(0.8)
65.9
0.2
101
44
25.4
80.7